Ondansetron Use During Pregnancy
Ondansetron is considered an acceptable antiemetic during pregnancy, with evidence supporting safety and efficacy for nausea and vomiting in pregnancy. [1] Ondansetron should not replace first-line therapies, but its use as a second-line option is not discouraged when first-line agents are ineffective. [1]
Guideline-Based Role in Nausea and Vomiting of Pregnancy
First-line antiemetics for nausea and vomiting in pregnancy include antihistamines and doxylamine/pyridoxine (Xonvea®). [1] Ondansetron has safety and efficacy data and should be used when first-line antiemetics are ineffective. [1]
Teratogenicity and Malformation Risk
A very small increase in the absolute risk of orofacial clefting has been reported with first-trimester ondansetron exposure. [1] Systematic review data show mixed results across orofacial cleft outcomes, with some signals for oral clefts and inconsistent findings for cleft palate. [2]
Practical Clinical Use Recommendations
Ondansetron use is most commonly positioned as second-line therapy for nausea and vomiting in pregnancy after insufficient response to first-line treatments. [1] Risk-benefit decision-making should balance the small potential orofacial cleft signal against risks of poorly controlled hyperemesis. [1]
Evidence Summary From Systematic Reviews
An updated systematic review and meta-analysis found increased odds for oral clefts and ventricular septal defects in some pooled analyses for first-trimester exposure. [2] The same meta-analysis reported no statistically significant association for major congenital malformations overall, and findings for cleft palate were not consistently significant. [2]
Safety Bottom Line for Counseling
Ondansetron is considered safe enough to be used during pregnancy when clinically indicated, particularly as second-line therapy for nausea and vomiting in pregnancy. [1] Counseling should include the presence of a very small absolute orofacial clefting risk signal with first-trimester exposure. [1]